^
    Back
    Association details:
    Biomarker:TROP2 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Datroway (datopotamab deruxtecan) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

    Published date:
    12/03/2021
    Excerpt:
    Dato-DXd also showed potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC PDX models.
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-21-0206